TransMedics Group (TMDX) Tops Q2 EPS by 14c ; Offers Guidance

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of $0.35, $0.14 better than the analyst estimate of $0.21. Revenue for the quarter came in at $114.3 million versus the consensus estimate of $98.96 million.

GUIDANCE:

TransMedics Group sees FY2024 revenue of $425-445 million, versus the consensus of $401.5 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Lockheed Martin wins $83 million Army missile contract
• Rocket Lab launches U.S. Space Force mission in record 16 hours